Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleUniversity College London Hospitals (UCLH) is the first in England to implement a new ovarian cancer surveillance test, Roca, for women with an inherited risk of the disease. The Roca test is designed for women with BRCA1 or BRCA2 gene mutations, who face a significantly higher risk of developing ovarian cancer. This blood test, taken every four months, calculates an individual's risk by tracking changes in CA 125 protein levels over time, even within normal ranges. It dramatically cuts the chance of being diagnosed with late-stage ovarian cancer, offering an alternative to immediate preventative surgery, which can lead to early menopause or prevent future childbearing. Professor Adam Rosenthal of UCLH expressed hope for a national programme to ensure all women with BRCA mutations can access this test, preventing a postcode lottery of care. In fullNew ovarian cancer test that detects risk of disease to be rolled outThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
New test cuts chance of late-stage ovarian cancer
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleUniversity College London Hospitals (UCLH) is the first in England to implement a new ovarian cancer surveillance test, Roca, for women with an inherited risk of the disease. The Roca test is designed for women with BRCA1 or BRCA2 gene mutations, who face a significantly higher risk of developing ovarian cancer. This blood test, taken every four months, calculates an individual's risk by tracking changes in CA 125 protein levels over time, even within normal ranges. It dramatically cuts the chance of being diagnosed with late-stage ovarian cancer, offering an alternative to immediate preventative surgery, which can lead to early menopause or prevent future childbearing. Professor Adam Rosenthal of UCLH expressed hope for a national programme to ensure all women with BRCA mutations can access this test, preventing a postcode lottery of care. In fullNew ovarian cancer test that detects risk of disease to be rolled outThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
